Lupin signs patent licence pact with Takeda for novel gastrointestinal drug in Indian market
Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialise Vonoprazan in India.
Home-grown pharma major Lupin Ltd on Wednesday said it has entered into a non-exclusive patent licence agreement with Takeda Pharmaceutical Company Ltd to commercialise Vonoprazan tablets, a novel gastrointestinal drug, in the Indian market.
Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialise Vonoprazan in India, the company said in a regulatory filing.
The drug will be marketed under the brand name Lupin's Lupivon and will be available in two strengths -- 10 mg and 20 mg, it added.
Lupin President India Region Formulations Rajeev Sibal said Vonoprazan is a novel treatment option for acid peptic disorders.
The pact with Takeda is "a further step in strengthening our gastroenterology portfolio and is in line with our commitment to introduce innovative medicines to address unmet needs of our patients," he added.
In India, Vonoprazan is approved by the DCGI (Drugs Controller General of India) for treating reflux esophagitis, gastric ulcers, duodenal ulcers, and as part of Helicobacter pylori eradication treatment, Lupin said in the filing.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Senior Citizen Latest FD Rates: Know what major banks like SBI, PNB, Canara Bank, HDFC Bank, ICICI Bank are providing on fixed deposits
Gratuity Calculator: Rs 38,000 as last-drawn basic salary, 5 years and 5 months of service; what will be gratuity amount?
EPFO Pension Schemes: Early pension, retirement pension, nominee pension and 4 other pension schemes that every private sector employee should know
Top 5 Small Cap Mutual Funds with best SIP returns in 1 year: See how Rs 25,000 monthly investment has grown in each scheme
Top 7 SBI Mutual Funds With Best SIP Returns in 1 Year: Rs 25,000 monthly SIP investment in No.1 fund has jumped to Rs 3,58,404
02:56 PM IST